CO4990969A1 - Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol - Google Patents

Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol

Info

Publication number
CO4990969A1
CO4990969A1 CO99008188A CO99008188A CO4990969A1 CO 4990969 A1 CO4990969 A1 CO 4990969A1 CO 99008188 A CO99008188 A CO 99008188A CO 99008188 A CO99008188 A CO 99008188A CO 4990969 A1 CO4990969 A1 CO 4990969A1
Authority
CO
Colombia
Prior art keywords
carbon atoms
integer
alkyl
range
independently represent
Prior art date
Application number
CO99008188A
Other languages
English (en)
Inventor
Chan Chuen
Caroline Mary Cook
Brian Cox
Richard Peter Charles Cousins
Joan Dyke Hazel
Frank Ellis
Joanna Victoria Geden
Stephen Swason
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313119&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4990969(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9803169.3A external-priority patent/GB9803169D0/en
Priority claimed from GBGB9813533.8A external-priority patent/GB9813533D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO4990969A1 publication Critical patent/CO4990969A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Abstract

Un compuesto de la fórmula (I): Caracterizado porque R1 y R2 representan independientemente un grupo seleccionado de : (i) cicloalquilo- de 3 a 8 átomos de carbono; (ii) hidrógeno, (iii) aril2 CHCH2 -; (iv) cicloalquil3-8 Calquilo- de 1 a 6 átomos de carbono; (v) alquilo- de 1 a 8 átomos de carbono;(vi) arilalquilo- de 1 a 6 átomos de carbono; o (vii) R4 R5 N-alquilo- de 1 a 6 átomos de carbono;(viii) alquil1-6 C-CH(CH2 OH)-;(ix) arilalquil1-5 C-CH(CH2 OH)-;(x) arilalquil1-5 C-C(CH2 OH)2 -;(xi) cicloalquilo de 3 a 8 átomos de carbono independientemente sustituido por uno o más grupos -(CH2 )p R6 ; (xii) H2 NC(=NH)NHCalquilo- de 1 a 6 átomos de carbono; (xiii) un grupo de la fórmulao tal grupo e el cual un átomo de carbono de metileno adyacente a X, o tanto si tal existe, se sustituye por metilo; (xiv) alquil1-6 C-OH;(xv) haloalquilo de 1 a 8 átomos de carbono;(xvi) un grupo de la fórmula - 2 -(xvii) arilo; y (xviii) -(CH2 )f SO2 NHg (alquilo de 1 a 4 átomos de carbono)2-g O -(CH2 )f SO2 NHg (arilalquilo de 1 a 4 átomos de carbono)2-g ; R3 representa metilo, etilo, -CH=CH2 , n-propilo, CH2 CH=CH2 , -CH=CHCH3 , isopropenilo, ciclopropilo, ciclopropenilo, -CH(OH)CH3 , -(CH2 )q halógeno, -(CH2 )h Y(CH2 )i H, -COO(CH2 )1 H, -CON(CH2 )m H((CH2 )n H), -CO(CH2 )o H, o -C((CH2 )u H)=NO(CH2 )v H; Y representa O, S o N(CH2 )j H; a y b representan independientemente un número entero de 0 a 4 con la condición que a + b esté en la gama de 3 a 5; c, d y e representan independientemente un número entero de 0 a 3 con la condición que c + d + e esté en la gama de 2 a 3; f representa 2 o 3 y g representa un número entero de 0 a 2; p representa 0 o 1; q representa 1 o 2; h representa 1 o 2 e i representa un número entero de 0 a 1; tal que h+i está en la gama de 1 a 2; j representa un número entero de 0 a 1 tal que h+i+j está en la gama de 1 a 2; l representa 1 o 2; m y n representan independientemente un número entero de 0 a 2 tal que m+n esté en la gama de 0 a 2; o representa un número entero de 0 a 2; u y v representan independientemente 0 o 1 tal que u+v está en la gama de 0 a 1;R4 y R5 representan independientemente hidrógeno, alquilo de 1 a 6 átomos de carbono; arilo, arilalquilo- de 1 a 6 átomos de carbono o NR4 R5 conjuntamente pueden presentar piridinilo, pirrolidinilo, piperidinilo, morfolinilo, azetidinilo, azepinilo, piperazinilo o N-alquil1-6 Cpiperazinilo; R6 representa OH, NH2 , NHCOH3 o halógeno; R7 representa hidrógeno, alquilo de 1 a 6 átomos de carbono, alquil1-6 Carilo o -COCalquilo de 1 a 6 átomos de carbono; X representa NR7 , O, S, SO o SO2 ; Y sales y solvatos del mismo.
CO99008188A 1998-02-14 1999-02-11 Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol CO4990969A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9803169.3A GB9803169D0 (en) 1998-02-14 1998-02-14 Chemical compounds
GBGB9813533.8A GB9813533D0 (en) 1998-06-23 1998-06-23 Chemical compounds

Publications (1)

Publication Number Publication Date
CO4990969A1 true CO4990969A1 (es) 2000-12-26

Family

ID=26313119

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99008188A CO4990969A1 (es) 1998-02-14 1999-02-11 Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol

Country Status (32)

Country Link
US (1) US6610665B1 (es)
EP (1) EP1056759B1 (es)
JP (1) JP2002503669A (es)
KR (1) KR20010082512A (es)
AP (1) AP2000001881A0 (es)
AR (1) AR017457A1 (es)
AT (1) ATE223429T1 (es)
AU (1) AU757156B2 (es)
BR (1) BR9907886A (es)
CA (1) CA2319009A1 (es)
CO (1) CO4990969A1 (es)
DE (1) DE69902758T2 (es)
DK (1) DK1056759T3 (es)
EA (1) EA200000759A1 (es)
EE (1) EE200000358A (es)
ES (1) ES2183516T3 (es)
HK (1) HK1032062A1 (es)
HR (1) HRP20000538A2 (es)
HU (1) HUP0100702A3 (es)
IL (1) IL137402A0 (es)
IS (1) IS5576A (es)
MA (1) MA27121A1 (es)
NO (1) NO20004045D0 (es)
NZ (1) NZ505812A (es)
PE (1) PE20000270A1 (es)
PL (1) PL342396A1 (es)
PT (1) PT1056759E (es)
SK (1) SK12002000A3 (es)
SV (1) SV1999000016A (es)
TR (1) TR200002355T2 (es)
WO (1) WO1999041267A1 (es)
YU (1) YU50800A (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) * 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) * 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ATE246701T1 (de) 1998-06-23 2003-08-15 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
GB9930075D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CN105078978A (zh) 2009-08-17 2015-11-25 因特利凯公司 杂环化合物及其用途
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
MX2017001461A (es) 2014-07-31 2017-05-11 Novartis Ag Terapia de combinacion.
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414193D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CO4990969A1 (es) * 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ATE246701T1 (de) * 1998-06-23 2003-08-15 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate

Also Published As

Publication number Publication date
WO1999041267A1 (en) 1999-08-19
ES2183516T3 (es) 2003-03-16
EP1056759B1 (en) 2002-09-04
EE200000358A (et) 2001-10-15
SV1999000016A (es) 1999-10-27
HK1032062A1 (en) 2001-07-06
PL342396A1 (en) 2001-06-04
DE69902758D1 (de) 2002-10-10
AU2623599A (en) 1999-08-30
PE20000270A1 (es) 2000-05-20
TR200002355T2 (tr) 2000-11-21
CA2319009A1 (en) 1999-08-19
BR9907886A (pt) 2000-10-17
YU50800A (sh) 2003-04-30
HUP0100702A2 (hu) 2002-01-28
IL137402A0 (en) 2001-07-24
NO20004045L (no) 2000-08-11
AP2000001881A0 (en) 2000-09-30
EA200000759A1 (ru) 2001-04-23
AR017457A1 (es) 2001-09-05
NZ505812A (en) 2002-03-01
US6610665B1 (en) 2003-08-26
HRP20000538A2 (en) 2000-12-31
PT1056759E (pt) 2003-01-31
NO20004045D0 (no) 2000-08-11
DK1056759T3 (da) 2003-01-06
DE69902758T2 (de) 2003-05-15
JP2002503669A (ja) 2002-02-05
ATE223429T1 (de) 2002-09-15
KR20010082512A (ko) 2001-08-30
HUP0100702A3 (en) 2003-01-28
EP1056759A1 (en) 2000-12-06
AU757156B2 (en) 2003-02-06
MA27121A1 (fr) 2005-01-03
IS5576A (is) 2000-07-25
SK12002000A3 (sk) 2001-07-10

Similar Documents

Publication Publication Date Title
CO4990969A1 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
CO4980872A1 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
YU47122B (sh) 5-deoksi-5-fluorocitidinski derivati
CO4950536A1 (es) Compuestos calciliticos
HUP0001353A2 (hu) Eljárás rákellenes hatású kinazolinszármazékok előállítására és az eljárás intermedierjei
GR3022853T3 (en) Alkoxy substituted taxanes as antitumour agents
UA76409C2 (uk) Трифенілалкенові похідні і їх застосування як селективних модуляторів рецепторів естрогену
CO5690506A2 (es) Derivados plaguicidas de 5-(acilamino) pirazoles
HUT57751A (en) Process for producing 2-(substituted phenyl)-2-oxazoline or triazoline derivatives, as well as insecticidal and acaricidal compositions comprising same
ES481549A1 (es) Un procedimiento para la producicion de un derivado de feni-letanolamina.
CO5031246A1 (es) Compuestos calciliticos
CO5611152A2 (es) Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen
ES376788A1 (es) Procedimiento para la preparacion de derivacion de alcano- lamina.
ES440426A1 (es) Un procedimiento para la preparacion de derivados de tieno- tiacina.
ES448475A1 (es) Procedimiento de preparacion de derivados triyodados del benceno.
ES269967A1 (es) Un procedimiento para la preparaciën de pirazolonas sustituidas
CO5690507A2 (es) Composiciones plaguicidas
RO81351B (ro) Procedeu pentru prepararea unor derivati de benzodiazepinei
IE41251L (en) 1, 4-dihydropyridines
AR035486A1 (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular y/o inhibir la actividad de erab/hadh2
ES428267A1 (es) Procedimiento para la produccion de derivados de guanidina.
ES415021A1 (es) Un procedimiento para la preparacion de compuestos de tria-zina.
ES8307818A1 (es) Procedimiento para preparar derivados de cefalosporina.
GB953909A (en) Bis-hydrazone antiozonants and rubber compositions
PT79214A (en) Derivatives of 4-(3-alkynyloxy-2-hydroxy-propyl)-piperazin-1-yl-n-acetamide